



Press Release

At Oxford Immunotec: Dr Peter Wrighton-Smith, CEO Tel: +44 (0)1235 442780 Fax: +44 (0)1235 442781 Email: info@oxfordimmunotec.com	Oxford Immunotec 94C Milton Park Abingdon Oxfordshire OX14 4RY, UK	Oxford Immunotec, Inc, 2 Mount Royal Avenue, Marlborough, MA 01752
--	---	--

AMA establishes a new CPT[®] Code for use with the T-SPOT[®].TB test

Oxfordshire UK [Marlborough, MA]; December 20, 2010 –

Oxford Immunotec, Inc. announces that a new and specific Current Procedural Terminology (CPT[®]) code has been established by the American Medical Association for use with the T-SPOT[®].TB test. The new Category I code, 86481, is described as “Tuberculosis test, cell mediated immunity antigen response measurement; enumeration of gamma interferon-producing T-cells in cell suspension.” This new code will be effective as of January 1, 2011.

The T-SPOT.TB test is based on a patented enzyme-linked immunospot (ELISpot) technology which is a highly accurate and innovative way to measure T-cell response. The T-SPOT.TB test measures the patient’s immune response to T-cells that have been sensitized to *Mycobacterium tuberculosis*, the bacterium that causes tuberculosis infection.

The T-SPOT.TB test received premarket approval from the Food and Drug Administration (FDA) in July 2008. The test is backed by the clinical evidence of over 200 peer-reviewed publications, and is the only TB screening test with sensitivity and specificity exceeding 95% in FDA pivotal trials. The T-SPOT.TB test has become widely utilized in hundreds of hospitals, medical practices and public health facilities throughout the United States.

Commenting on the new code, Dr. Peter Wrighton-Smith, CEO of Oxford Immunotec, said, “By choosing the T-SPOT.TB test, our customers have shown their trust in our test and the technology platform upon which it is run. I am pleased that the American Medical Association agrees that the ELISpot platform is a unique and powerful technology. The establishment of this new code will improve access to the test and make it more available to physicians and hospitals.”

- Ends-

Notes to Editors:

About Oxford Immunotec
www.oxfordimmunotec.com

Oxford Immunotec Ltd., the T cell measurement company, is headquartered near Oxford, UK; its US operations are based in Marlborough, MA. The company develops and sells clinical diagnostic products based on its patented T-SPOT[®] technology, the first FDA-approved method for directly quantifying antigen-specific T cells.

T-SPOT technology is a simple and extremely accurate method of studying a person's cellular immune response to infection and could be applied to diagnose and monitor any major disease driven by a T cell response.

About T-SPOT[®].TB test

The T-SPOT.TB test is an *in vitro* T cell measurement assay used for diagnosing TB disease and latent TB infection and is the first product from Oxford Immunotec using T-SPOT technology. The product offers unrivalled sensitivity with results unaffected by a patient's immune status. The T-SPOT.TB test is approved for sale in Europe, USA, Canada and over 40 other countries worldwide and is designed to replace the 115 year old tuberculin skin test. It offers a substantially more accurate and effective tool for controlling the spread of TB, addressing a market exceeding \$1bn.

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.

CPT is a registered trademark of the American Medical Association